Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
Eli Lilly lifts 2024 sales view by $2 billion on weight-loss drug demand Updated / Tuesday, 30 Apr ... The drugmaker also raised its annual profit forecast by $1.30 per share to $13.50 to $14 per ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Eli Lilly and Company se dedica al negocio de fabricación de medicamentos. La Compañía descubre, desarrolla, fabrica y comercializa productos en dos segmentos: Productos farmacéuticos para ...
Eli Lilly and Company se dedica al negocio de fabricación de medicamentos. La Compañía descubre, desarrolla, fabrica y comercializa productos en dos segmentos: Productos farmacéuticos para ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...